Nabla
Ambient AI copilot that turns doctor-patient conversations into clinical notes in seconds — so clinicians can focus on care, not paperwork.
Overview
Nabla is a Paris-founded ambient AI assistant built for clinicians. It listens to patient consultations in real time and automatically generates structured clinical notes, SOAP summaries, medical coding suggestions, and patient-friendly summaries — all embedded directly into major EHR platforms including Epic, Oracle Health, athenahealth, NextGen, and Greenway. Launched in March 2023, it reached 85,000+ clinicians across 150+ health organisations by mid-2025, processing over 20 million patient encounters per year. A randomised trial published in NEJM AI found Nabla users cut time-in-note by 9.5% versus controls, outperforming Microsoft DAX in that study's primary efficiency metric.
Beyond documentation, Nabla has moved toward an agentic clinical platform following its $70 million Series C in June 2025 (led by HV Capital; total raised $120 million). New capabilities include real-time medical coding, pre-charting, nursing workflows, and custom department-level agents that connect to legacy systems via API. The platform is HIPAA, GDPR, SOC 2 Type 2, and ISO 27001 certified, stores no audio by default, and does not train models on customer data. Nabla does not currently disclose a public valuation; the $5.3B figure circulating in some secondary sources is unverified and should not be taken as confirmed.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 16 Jun 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
Use cases
What you can produce with Nabla
- Structured clinical note (SOAP or custom format) generated automatically within seconds of a consultation
- ICD-10 and medical coding suggestions surfaced in real time during or after the patient encounter
- Patient-friendly visit summary ready for sharing immediately after the appointment, in the patient's selected language
- Custom note templates per specialty or department, adjustable by clinicians via the Nabla dashboard
- EHR-embedded documentation pushed directly into Epic, athenahealth, Oracle Health, or other integrated systems without copy-paste
- Agentic coding and billing audit flags that identify documentation gaps before claim submission
- API access for enterprise health systems building custom clinical workflow integrations via the Nabla Core API
ASEAN Perspective
Nabla in Southeast Asia
Nabla has no confirmed presence, partnerships, or regulatory clearances in ASEAN markets as of mid-2026. Its language support, while marketed broadly, is publicly confirmed for English, Spanish, and French — coverage of regional languages such as Bahasa Melayu, Bahasa Indonesia, Thai, Vietnamese, or Filipino is unverified. ASEAN clinicians working within English-language healthcare settings (such as Singapore's private hospital sector) may find the core ambient transcription useful, but EHR integration support for regional systems like iHIS or local hospital platforms has not been announced. Healthcare AI buyers in the region should assess data residency requirements carefully, as Nabla's infrastructure is US/EU-centric and PDPA or national health-data localisation rules may apply.
Nabla delivers one of the most clinically validated ambient AI scribes on the market. A NEJM AI randomised trial across 238 physicians and 48,000+ visits found a statistically significant 9.5% reduction in documentation time — a concrete evidence base most competitors lack. The platform's breadth (55+ specialties, 35+ languages, 20+ EHR integrations) and agentic roadmap (coding, nursing, custom department agents) give it real staying power among mid-to-large health systems. Reported outcomes are strong: 55% of users save at least one hour per day, 90% user retention, and a 27% burnout reduction at surveyed sites.
That said, Nabla is not without caveats. Pricing has shifted to opaque, contract-driven enterprise tiers in 2026, making independent cost comparison difficult for smaller practices. Language support, while marketed as multilingual, is publicly confirmed only for English, Spanish, and French; broader coverage requires verification with sales. There is no confirmed NHS deployment or APAC expansion to date — the tool's footprint is overwhelmingly US-centric. The published $5.3B valuation figure is unverified; Nabla has not disclosed a post-Series-C valuation. Clinicians should trial the free tier carefully before committing to an enterprise contract.
What people say
Nabla is one of the better-evidenced ambient AI scribes, with a peer-reviewed NEJM AI randomized trial across 238 physicians showing a statistically significant 9.5% drop in documentation time. Reported real-world outcomes include 55% of clinicians saving at least one hour of documentation time (Carle Health pilot) and roughly 26% burnout reduction in a 5-week Iowa pilot (exceeding 30% by 30–90 days system-wide). Onboarding is fast, often within a single session, and the product supports 35+ languages. Main caveats: opaque enterprise pricing, a US-led deployment footprint with only emerging APAC activity (e.g. New Zealand GP/ProCare evaluation), and no verified NHS contract.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Nabla co-founder Alex Lebrun previously sold two AI companies — VirtuOz to Nuance (2013) and Wit.ai to Facebook (2015) — before founding Nabla, giving the team direct roots in both conversational AI and medical NLP.
- The founding team ran their own UK-based clinics for a full year before writing a single line of product code, to understand physician workflow firsthand.
- Nabla was the first healthcare AI company to publish a CHAI Applied Model Card — a governance transparency disclosure aligned with the Coalition for Health AI standards.
- Yann LeCun, the Turing Award-winning deep learning pioneer, was an early investor in Nabla, and in late 2025 his new research company Advanced Machine Intelligence entered an exclusive partnership with Nabla to build FDA-certifiable agentic clinical AI.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Nabla's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Nabla unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Nabla directly →
Spotted something out of date? Suggest an update →
Alternatives to Nabla
More in Productivity
